Trials / Completed
CompletedNCT04315688
A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Russia
A Prospective Non-interventional Study Investigating the Treatment Effect of Tresiba® in Adult Patients With Type 2 Diabetes in Russia
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 494 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to collect information on how Tresiba® works in real world patients with Diabetes Mellitus, Type 2 (type 2 diabetes). Participants will get Tresiba® as prescribed by their doctor. The study will last for around 6 to 8 months. Participants will be asked questions about their health and their diabetes treatment as part of their normal doctor's appointment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | insulin degludec | Treatment with Tresiba® with or without anti-diabetes medication (as per local label), as prescribed by the participant's physician. The study population will include adult patients with type 2 diabetes, both insulin naïve and previously insulin treated, for whom the treating physician has decided to initiate treatment with Tresiba®, independent of the decision to include the patient in the study. |
Timeline
- Start date
- 2020-03-30
- Primary completion
- 2021-08-02
- Completion
- 2021-08-02
- First posted
- 2020-03-19
- Last updated
- 2021-08-23
Locations
40 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT04315688. Inclusion in this directory is not an endorsement.